TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Government & Organizations

    The Long Run with Luke Timmerman

    “The Long Run”

    Antarctic explorer Ernest Shackleton would appreciate today’s biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.

    Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

    Advertise

    Copyright: © All rights reserved

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    Ep200: Richard Pops Reflects on a 35-Year Career in Biotech May 05, 2026
    Show notes

    Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.


    Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era Apr 21, 2026
    Show notes

    Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.


    Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery Apr 07, 2026
    Show notes

    Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.


    Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature Mar 31, 2026
    Show notes

    Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.


    Ep196: Otello Stampacchia on Europe's Biotech Crisis Mar 17, 2026
    Show notes

    Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.


    Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases Mar 03, 2026
    Show notes

    Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.


    Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery Feb 17, 2026
    Show notes

    Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report


    Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines Jan 22, 2026
    Show notes

    Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.


    Ep192: Kate Haviland on Following the Science to Precision Immunology Jan 08, 2026
    Show notes

    Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.


    Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease Dec 15, 2025
    Show notes

    Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).


    Previous 1 2 3 4 21 Next

    Related Podcasts

    The Joe Rogan Experience

    1

    The Joe Rogan Experience Comedy
    More Perfect

    2

    More Perfect Government
    Casefile True Crime

    3

    Casefile True Crime Games & Hobbies
    Reply All

    4

    Reply All Games & Hobbies
    You Must Remember This

    5

    You Must Remember This Games & Hobbies
    Real Time with Bill Maher

    6

    Real Time with Bill Maher Games & Hobbies
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights